Results 261 to 270 of about 2,641,102 (341)

843 Improving the selection of fiducial-less lung patients for CyberKnife radiosurgery: Recommendations for patient selection, simulation and workflow

Milad Mirzaei, Nicholas Bucknell, Joshua Dass, Angela Jacques, Clare E Herbert, Martin A. Ebert, Sean Bydder   +6 more
openalex   +2 more sources

Role of Detection of Early Response of Apoptosis in Patient Selection for Continuation of Preoperative Chemoradiation Therapy for Lower Rectal Cancer.

, 2000
Y. Ogata, Shunsuke Mori, Yoshito Akagi, H Kamei, K. Tokuhara, Yasunari Miyagi, M. Kanazawa, Yasuhiro Nozoe, Hitoshi Oda, Kiyohisa INUZUKA, NAOFUMI HAYABUTI, Kazuo Shirouzu   +11 more
openalex   +2 more sources

Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma

Molecular Oncology, EarlyView.
PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga, María Luz Martinez‐Chantar, Carolina Conter   +2 more
wiley   +1 more source

Gene- and immune-targeted therapy combinations using dual-matched biomarkers for patient selection. [PDF]

NPJ Precis Oncol
Nishizaki D, Kurzrock R, Adashek JJ, Kim KH, Lim HJ, Nikanjam M, Eskander RN, Fanta PT, Okamura R, Lee S, Sicklick JK, Lippman SM, Kato S.   +12 more
europepmc   +1 more source

Flowchart of Patient Selection.

Jinfeng Lin (10189281), Zhilong Cao (22411049), Chunfeng Gu (22173121), Lijun Tian (6106226), Yadong Wang (82064), Xudong Han (6702437)   +5 more
openalex   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Proper Patient Selection and Choosing the Right Treatment: The Recipe for Good Clinical Outcomes. [PDF]

Arthrosc Sports Med Rehabil
Gaschen PD, Kraeutler MJ.
europepmc   +1 more source

Patient-reported outcome measures for use in patients with alpha-1-antitrypsin deficiency: results of a systematic selection process

Karolina Müller, Louisa Vogl, Helge Knüttel, Timm Greulich, F Lammert, Pavel Strnad, Claus Vogelmeier, Marion Wilkens, Robert Bals, Michael Koller   +9 more
openalex   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source